Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03379441
Title Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC (MP-LALC)
Acronym MP-LALC
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Turin, Italy
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Facility Status City State Zip Country Details
CRO Aviano Aviano Pordenone 33081 Italy Details
AOU San Luigi- Department of Oncology Orbassano Turin 10043 Italy Details
Istituto Tumori Giovanni Paolo II Bari 70124 Italy Details
Chieti Università degli Studi "G. D'Annunzio" Chieti 66100 Italy Details
AOU Careggi Firenze 50134 Italy Details
IRCCS AO San Martino Genova 16132 Italy Details
Azienda Ospedaliera Papardo Messina 98158 Italy Details
Istituto Clinico Humanitas Milano 20089 Italy Details
Ospedale San Raffaele Milano 20132 Italy Details
Policlinico Modena Modena Italy Details
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Napoli 80131 Italy Details
Policlinico Universitario Campus Biomedico Roma 00128 Italy Details
PO Centrale Taranto 74100 Italy Details
Policlinico Verona Borgo Roma Verona 37134 Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field